irreversible lung damage are still poorly defined. Several studies suggest that CFTR deficiency is linked to abnormal dysregulated inflammatory response (4, (6) (7) (8) (9) (10) (11) (12) . Recently, Teichgraber et al (12) showed that an abnormal ceramide accumulation occurs in the respiratory tract of uninfected CFTR-deficient mice, as well as in respiratory epithelial cells of subjects with cystic fibrosis, as a consequence of the CFTR defect, and that it leads to constitutive increased inflammatory response, respiratory epithelial cell death, and high susceptibility to severe P. aeruginosa infection. The accumulation of ceramide on the respiratory epithelium may still increase after the onset of chronic P. aeruginosa infection, inducing a vicious cycle that augments tissue destruction and remodeling by increasing inflammation. These results provide evidence that inflammation is prior to infection in CF airways, and support the concept that a vicious cycle between inflammation and infection occurs: the persistent bacterial pathogens are stimulating the chronic production of pro-inflammatory stimuli which maintain airway inflammation and induce lung damage in CF.
In this study, to gain further insight into the mechanisms of inflammatory damage in CF airways, we used a novel model that closely mimics the pathophysiological events occurring in CF airways: we obtained sputum sol phase from CF patients both at clinical stability and at the time of acute exacerbations and evaluated a) its effect on adhesion molecule expression by human microvascular endothelial cells, which plays a crucial role in neutrophil recruitment and migration, and b) its capability of inducing apoptosis in wild-type and CFTR-defective airway epithelial cells.
MATERIALS AND METHODS

Patients
Airway secretions were obtained from IS adult patients with CF attending our CF Centre at the Respiratory Disease Division, University of Turin. The diagnosis of CF was based on a typical clinical profile with a positive sweat test and/or identification of mutations in both alleles of the CFTR gene. Sputum was obtained from 7 CF patients who had not had an acute pulmonary exacerbation during the previous two months and were not taking antibiotics, non-steroidal anti-inflammatory drugs or corticosteroids over the same periods (stable patients) and from 8 patients admitted to the hospital for an acute pulmonary exacerbation (acute patients), immediately before any treatment was started. A pulmonary exacerbation was defined as the presence of at least three of the following signs and symptoms: an increase in sputum purulence and volume, and increased respiratory rate or dyspnea, increased cough, weight loss and anorexia, temperature above 38°C on more than one occasion in the previous week, new findings on chest radiograph, or a decrease in Forced Expiratory Volume in I sec (FEVl) of 10% or more from previous best (13) . Chronic infection was defined as persistent growth of bacteria for 6 months or more, continuously.
The study conformed to the declaration of Helsinki and written informed consent was obtained from all subjects.
Sputum collection and processing
Sputum was diluted 1:2with sterile phosphate-buffered saline, and gently agitated to uniform consistency. Sputum Sol Phase (SSP) was obtained by sputum centrifugation at 30,000 x g for 40 min. at 4°C and filtration with 0.45 urnpore filters, and stored at -80 0 C until used for the different experiments.
Cell culture and treatment
Human microvascular endothelial cells (HMECs) were cultured in MI99 medium (Bio Whittaker Europe, Verviers, Belgium) with 20% Foetal Calf Serum (FCS) (GIBCO, Grand Island, NY), endothelial cell growth factor (100 ug/ml) (Sigma Chemical Co., St Louis, MO), porcine heparin (Sigma) (100 ug/ml), 200 U/ml penicillin and 0.2 mg/ml streptomycin, in 6 or 24 well culture plates, in a humidified atmosphere of air and 5% CO 2 at 37°C, as previously described (14) .
The human bronchial epithelial (HBE) cell line 16HBE140-was a kind gift from Dr. Dieter C. Gruenert (California Pacific Medical Center Research Institute, San Francisco, USA). This cell line was generated by transformation of normal bronchial epithelial cells obtained from a I-year-old heart-lung transplant patient (15) . The two human bronchial epithelial cell lines, 16HBE-S I (transfected with the first 131 nucleotides of human CFTR in the sense orientation: wild-type cells) and 16HBE-AS3 (transfected with the first 131 nucleotides of human CFTR in the antisense orientation: CFTRdefective cells) were derived from the parental cell line and were a kind gift from Dr. Alice Prince (Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, USA).
Epithelial cells were grown on fibronectin-coated well culture plates in MEM-Earle's Salts (Gibco) supplemented with 10% Foetal Bovine Serum (FBS), glutamine (2 mM), 100 U/ml penicillin, 100 U/ml streptomycin, 400 ug/ml geneticin (Gibco), and incubated at 37°C in an atmosphere of air and 5% CO 2 , Cells transfected with the sense construct had a significant cAMP-stimulated increase in chloride efflux studies, whereas the cells transfected with antisense did not. Monolayers of antisense cells studied in an Ussing chamber did not display chloride secretion in response to amiloride followed by forskolin (16) .
Morphological changes were assessed by examination of the cells in an inverted-phase contrast microscope (DM IRB HC model; Leica Microsystems, Bensheim, Germany).
Isolation ofpolymorphonuclear neutrophils
Polymorphonuclear neutrophils (PMNs) were isolated from peripheral blood of healthy volunteers by standard dextran sedimentation followed by Ficoll-Hypaque gradient centrifugation. The PMNs were resuspended in buffered salt solution (BSS) supplemented with I mg/ml glucose and I mg/ml human serum albumin (HSA). Purity of the final cell suspension averaged 98%. PMN viability (as assessed by the trypan blue exclusion test) was always greater than 95%.
Viability Assay
Cell viability was determined by measuring the ability of cells to metabolize MTT (Sigma-Aldrich, Milano, Italy), a water-soluble tetrazolium salt, into a waterinsoluble formazan product (17) and by Trypan Blue dye exclusion test.
Flow cytometry
To evaluate the effect of SSP from CF patients on adhesion molecule expression by HMECs, cells were cultured in complete medium (see above), in the absence or presence of SSP (diluted I :5) obtained from both stable and acute CF patients, and incubated at 37°C in 5% CO 2 for various times (6-48 hours). In some experiments, neutralizing anti-TNF -a. antibodies (Bender MedSystem, Wien, Austria, final concentration: 10 ug/ml) or anti-IL-I pantibodies (Bender MedSystem, final concentration: 5 ug/rnl) or anti-IFN-y antibodies (Bender MedSystem, final concentration: 20 ug/ml) or anti-IL-8 antibodies (R & D Systems Europe Ltd, UK, final concentration: 20 ug/ml) or a.l-antitrypsin (a.l-AT, Calbiochem, La Jolla, CA, final concentration: 133 ug/ml) were added to the cell cultures. Single-cells suspensions of HMECs were then recovered and incubated with FITC-conjugated anti-ICAM-I monoclonal antibody (Becton Dickinson, San Jose, CA) or FITC-conjugated anti-E-selectin monoclonal antibody (Bender MedSystems) or FITC-conjugated anti-VCAM-I monoclonel antibody (Bender MedSystems) for 30 min at 4°C. Cells were then washed and labeled with propidium iodide (Sigma). The propidium iodide-negative quadrants of the analysis were considered healthy cells; the cells were gated based on the Side and Forward Scatter parameters. The expression of ICAM-I, VCAM-I and E-selectin on HMECs was evaluated by flow-cytornetric analysis, using a FACScan flow cytometer (FACSCalibur, Becton Dickinson), as previously described (18) .
s-ICAM-I assay
HMECs were cultured for 24 or 48 hours, in the absence or presence of SSP (diluted 1:5) from both stable or acute patients, and with or without the addition of the neutrophil elastase inhibitor a.l-AT (final concentration: 133 ug/ml). Levels of the soluble form of ICAM-I (s-ICAM-I) in the cell supernatants were determined by commercially available ELISA (Bender Med-Systems, Wien, Austria), according to the procedure recommended by the manufacturer. All measurements were performed in duplicate. The reported sensitivity of the assay was 3.3 ng/ml,
Measure of human neutrophil elastase activity in SSP samples
Elastase-specific proteolytic activity in SSP samples was measured by a standard colorimetric assay using the chromogenic peptide N-methoxysuccinyl-Ala-AlaPro-Val-p-nitroanilide (Sigma) as substrate. Briefly, SSP samples were incubated with HEPES (0.1 M) buffer containing NaCI (0.5 M), 10% dimethylsulfoxide, and substrate (2 mM) at pH 7.5. The amount ofp-nitroanilide liberated was measured spectrophotometrically at 405 nm. Human neutrophil elastase (HNE, Calbiochem) at a concentration of 2.5 ug/rnl was used as a positive control. To assess the inhibitory effect of a.I-AT on HNE activity, SSP samples were incubated with this inhibitor (133 J-lg/ ml) for 30 min before the assay.
Adhesion assay
HMECs were grown to confluence in 24-well plates and treated with SSP at the same concentration as above. PMNs (10 6 cells/ml) were labeled with fluoresceine diacetate (5 J-lg/ml)(Sigma) for 30 minutes at 37°C, washed with PBS, and added to HMECs at a concentration of 10 6 cells/well. PMNs were allowed to adhere to HMECs for I hour. Unbound PMNs were then removed by washing three times with PBS and the plates were read at 525 nm by a microplate reader (Model HTS7000; Perkin-Elmer, Boston, MA). Binding was expressed as the mean binding of triplicate wells.
Cell death detection
HBECs were grown in 24-well culture plates for different times (24-36 hours) , in the presence or absence of SSP (diluted 1:5) from stable or acute patients. Cell death was measured by the "Cell Death Detection ELISA kit" (Roche) according to the manufacturer's instructions. Briefly, after incubation, the cells were collected, lysed, and transferred to microtiter plates containing streptavidin-coated wells. Nucleosomes were bound by two monoclonal antibodies, the "biotin labeled anti-histone" and the "peroxidase conjugated anti-DNA". Antibody-nucleosoma complexes were bound by the streptavidin contained in the microtiter plates. Finally, samples were incubated with a peroxidase substrate and the amount of DNA determined spectrophotometric ally at 405 nm.
Analysis of cytochrome c mitochondrial release by immunocytochemistry
To assess the possible involvement of the intrinsic apoptosis signalling, cytochrome c release from the mitochondria into the cytoplasm of the cells was evaluated.
After different incubation times (from 4 to 8 hours), cells were harvested, washed, and collected by cytocentrifugation at 50 g for 5 min on a glass slide using a Cytospin (Shandon, Italscientifica, Genova, Italy). The specimens were fixed in 95% ethanol for 5 min, permeabilised with MSM-PIPES [5 mM PIPES, 18 mM MgS0 4 , 5 mM CaC1 2 , 40 mM KCl, 24 mM NaCl, 0.5% Triton X-IOO (v:v), 0.5% Igepal CA-630 (v:v)] for 30 min at room temperature and incubated in a 100 mM sodium cyanoborohydride reducing agent for 10 min at 37°C. The slides were pre-incubated, to block non-specific binding, for 30 min at room temperature with 3% BSA in 0.01 M PBS (w:v) containing 5% normal goat serum (v:v) and 0.3% Tween 20 (v:v); then, an incubation in the presence of 10 ug/ml purified mouse anti-cytochrome c monoclonal antibody was carried out in a humidified chamber overnight at room temperature. Specimens were further incubated with a purified goat anti-mouse FITC-conjugated secondary antibody (7 ug/ml in 0.01 M PBS) at room temperature for 60 min and then sealed with glycerol after three additional washes with distilled water. In all cases, incubation was followed by washes with 0.1 M PBS for 5 min at room temperature. Cytochrome c mitochondrial release was detected by immunocytochemistry, using a laser scanning confocal microscope Zeiss LSM 510 (Carl Zeiss SpA, Arese, Milano, Italy) equipped with a Zeiss inverted fluorescence microscope with a 40x/0.75 "plan neofluar" objective (image size 0.053 mm 2). Exciting light intensity, black level, and photomultiplier gain were adjusted on control specimens; settings were the same for scanning experimental samples. The instrument was set to 488 nm exciting laser band, with a 515 nm long pass emission filter. The fluorescence intensity was expressed as mean ± standard error in arbitrary units of fluorescence (AUF)/pixel: the quantification was performed on ten different fields of each slide using a LSCM 510 Image Examiner Program from Zeiss.
Western blot analysis
After treatment in the presence or absence of SSP from CF patients, the cells were washed in PBS and lysed at 4°C in 1 ml/dish of lysis buffer [50 mM Tris HCl pH 7.4, 150 mM NaCl, 1% Triton X-I00 (Sigma-Aldrich, St Louis, USA), 10% glycerol], 1 mM PMSF, 1 mM Na ortho-vanadate, 100 flM zinc chloride and protease and phosphatase inhibitors (pepstatin, 50 ug/ml; leupeptin, 50 ug/ml, aprotinin, 10 ug/ml) (Sigma-Aldrich). Total celllysates Were incubated for 20 min on ice, centrifuged at 16.000 g for 10 min (4°C), and supernatants used for electrophoresis. Nuclear extraction was performed according to Parker and Topol procedure (19) .
Protein concentration of each sample was quantified by the "BCA protein assay reagent A" (Pierce, Rockford, USA).
Sample proteins were separated by electrophoresis in 8% or 12% (depending on the protein's molecular weights) SDS-PAGE followed by transfer to Hybond ECL nitrocellulose membranes. Immunodetection was performed using primary rabbit antibodies anti-caspase8, -procaspase3, -caspase3, -NFKB p65, -IKBa, and goat anti-NFKB p50 (Santa Cruz Biotecnology, CA) (1: 1000 dilution) followed by HRP-conjugated secondary antibodies (Amersham Pharmacia, Piscataway, USA) (1:5000 dilution). The "ECL Western Blotting System" (Amersham Pharmacia) was used for chemiluminescence detection. The protein bands obtained from whole cell extracts were normalized to actin.
Statistical analysis
Wilcoxon's matched pairs test was used to compare the levels ofICAM-l, VCAM-l and E-selectin expression on endothelial cells and the percentage of apoptotic cells in HBEC cultures, in the absence or presence of SSP from CF patients as well as in the absence or presence of the different inhibitors. Statistical significance was assumed for p values lower than 0.05. Data are expressed as mean ± standard error (SEM).
RESULTS
Patients
Seven patients with stable disease (stable patients) and eight patients with acute exacerbations (acute patients) were studied. Mean values (±SEM) for Forced Expiratory Volume in I sec (FEV!) and Forced Vital Capacity (FYC) were lower in acute patients (48.6±17.1, and 69.1±16% predicted, respectively) as compared with stable patients (54.2±18.6, and 77.6±25% predicted, respectively). All but two patients studied at stable clinical conditions and one patient studied at the time of an acute exacerbation, were chronically infected by P. aeruginosa, whereas three patients with stable disease and six patients with acute exacerbations were also chronically infected by S. aureus. The microorganisms responsible for acute exacerbations were A. xylosoxidans in one case and P. aeruginosa in seven cases, associated to S. aureus in three cases and to H. injluenzae in one case.
Effect ofsputum sol phase on adhesion molecule expression by HMECs
To rule out a toxic effect of SSP on endothelial cells, we performed preliminary experiments in which cells were cultured in the absence or presence of different concentrations of SSP (I :2, I :5, I: I0) from stable or acute patients for different periods of time, and cell viability was evaluated; for all experiments, we then used the maximal dilution (I: 5) that did not alter cell viability.
On the basis of time-course studies (6, 24, and 48 hours), ICAM-I and YCAM-I expression was assessed after 24 hours of cell incubation with SSP, as maximum effect was observed at this time-point; in contrast, E-selectin expression was assessed after 6 hours of incubation of cells with SSP, since the upregulation of this molecule was no longer detectable at 24 hours.
SSP obtained from stable patients induced a significant upregulation of ICAM-I (34.5±5.8% of positive cells) and E-selectin (13.6± 1.5%) expression on HMECs as compared with cells cultured in medium alone (24.4±5.2%, and 4.2±0.8%, respectively; p<0.05 for both comparisons); the upregulation of both these adhesion molecules was significantly more marked in the presence of SSP from acute patients (ICAM-I: 67.I±5.9%, Eselectin: 63.1±5.1%) as compared with cells cultured in medium alone (p<O.O I for both comparisons; Fig.  IAand B) .
No significant difference in the expression of YCAM-I was observed between cells cultured with SSP from stable patients (2I.7±6.9%) and cells cultured in medium alone (l7.2±5%); however, similarly to ICAM-I and E-selectin, a significant upregulation ofYCAM-1 was induced by SSP from acute patients (74.5±5. 
Involvement of inflammatory mediotors in adhesion molecule upregulation
To identify the inflammatory mediators responsible for the upregulation of endothelial adhesion molecules induced by SSPfrom CF patients, we tested the effect of neutralizing antibodies against TNF-a, IL-I~, IFN-y and IL-8. The addition of anti-IL-I and anti-TNF-a antibodies to the cell cultures induced a partial inhibition of E-selectin upregulation caused by SSP from stable (anti-ILl: 11.5±10% inhibition, anti-TNF-a: 39±1.5%, anti-Il--I + anti-TNF-a: 47±2.5%) or acute patients 64.4±11%) (Fig. 2 A, C ) . In contrast, no inhibitory effect was observed in the presence of anti-IFN-y or anti-IL-8 antibodies (data not shown). With regard to ICAM-I, both anti-IL-I and anti-TNF-a antibodies induced only a mild inhibition of the adhesion molecule upregulation induced by SSP from both stable (anti-IL-I: 13.5±2% inhibition, anti-TNFa: 14±2%, anti-IL-I + anti-TNF-a: 17±1%) or acute patients (anti-IL-I : 15±1.5%, anti-TNF-a: 17.2±4.5%, anti-IL-I + anti-TNF-a: 27.5±5%) (Fig.   2B ), whereas a stronger inhibition was induced by an anti-IFN-y antibody (50.8±4.5%), in the presence of SSP from acute patients; also in this case, no inhibitory effect was observed in the presence of an anti-IL-8 antibody (data not shown).
Previous studies have reported discrepant results on the effect of neutrophil elastase on ICAM I expression: Ishihara et al. (20) showed that neutrophil elastase enhances ICAM-I expression on endothelial cells, on the other hand Champagne et al. (21) reported that neutrophil elastase reduced ICAM-I expression on different human cell lines by inducing a dose-dependent proteolytic cleavage of ICAM-I. As CF sputum has been shown to contain high levels of neutrophil proteases (22) 
) or acute disease (Panel B). in the absence (grey curves) or presence (dotted curves) of al -antitrypsin. Cells were then immunostained with FITC-conjugated anti-ICAM-l mAb. Surviving cells were gated based on Side and Forward Scatter parameters and on Pl negative cells. The results of one representative experiment out of three independent experiments performed are shown. _ Effect of sputum sol phase on PMN adhesion to HMECs
To assess whether the increased expression of adhesion molecules induced by SSP was associated with an increase in PMN capability of adhering to endothelial cells, we pre-treated HMECs with SSP from both stable and acute CF patients and evaluated PMN adhesion to these cells.
As shown in Fig. 4 , pre-treatment of HMECs with SSP from acute patients resulted in a significant increase of PMN adhesion to these cells (p<0.05 as compared to cells pre-treated with SSP from stable patients or untreated cells).
and in some experiments, we evaluated ICAM-I expression on endothelial cells and the levels of the soluble form of this adhesion molecule (s-ICAM-1) in cell supernatants, in the absence or presence of the neutrophil elastase inhibitor a I-antitrypsin.
High levels of elastase activity were detected in SSP from both acute (240.5 ± 83.29 nM/ml) and stable patients (184,44± 117.18 nM/ml), which were almost completely inhibited by the incubation ofSSP with a I-AT for 30 min before the assay (12.20± 10.50, and 2.99±2.81 nM/ml, respectively).
The ICAM-1 upregulation induced by SSP from both stable or acute patients was not affected by the addition of a I-AT to the endothelial cell cultures (Fig. 3) 
Effect ofsputum sol phase on apoptosis ofwild-type human bronchial epithelial cells (HBECs)
To assess the effect of SSP from CF patients on wild-type and CFTR-defective HBECs, 16HBE 140-cells, (a continuous cell line generated by transformation of normal human bronchial epithelial cells), 16HBE-S I cells (transfected with the first 131 nucleotides of human CFTR in the sense orientation) and 16HBE-AS3 cells (transfected with the first 131 nuc1eotides of human CFTR in the antisense orientation) were treated with SSP from stable or acute patients for different times (24-36 hours). SSP from acute patients induced morphological alterations of both wild-type and CFTR-defective cells which heralded the activation of apoptotic pathway; these alterations were not observed in cells cultured with medium alone (data not shown).
The analysis of histone-associated DNA fragments in nuc1eosomes confirmed that SSP from CF patients with acute exacerbations induced a significant increase in the percentage of apoptotic cells in human bronchial epithelial cells (p<0.02 as compared with untreated cells); the increase in apoptosis was reduced by the addition of an anti- TNF-a antibody to the cell cultures, although control cell values were not reached. In contrast, no effect was observed in the presence of anti-IFN-y or antilL-I antibodies. The apoptotic effect induced by SSP from stable patients was weaker than that observed in cells treated with acute SSP (p<0.05 as compared with untreated cells Fig. SA) .
To confirm the involvement of the TNF-adependent apoptotic pathway activation, Western blot analysis was carried out on cell lysates of HBECs treated with SSP from CF patients: Fig.  5B shows the activation of caspase-S, as well as decreased level of procaspase-3 associated with caspase-3 activation, in HBECs treated with SSP from acute patients.
The incomplete apoptosis inhibition by an anti-TNF-a antibody observed in cells treated with SSP suggests a possible additional involvement of the intrinsic apoptosis signalling.
To verify this hypothesis cytochrome c release from the mitochondria into the cytoplasm of the cells was monitored immunocytochemically in cells treated with SSP from acute or stable patients, from 4 to 8 hours. The maximum release of cytochrome c was reached after 6 hours ( 
Effect of sputum sol phase on apoptosis of CFTRdefective human bronchial epithelial cells (HBECs)
Similar experiments were carried out using CFTR-defective cells: when we compared the apoptotic effect induced by SSP in wild type and CFTR-defective cells we observed that apoptosis was delayed in CFTR-defective cells in that it was observed after 36 hours of culture, whereas in wild-type cells it was already observed after 24 hours; furthermore, CFTR-defective cells seem to be less susceptible to apoptosis: indeed, after 36 hours of treatment with SSP from acute patients, 60.4% of wild-type cells were apoptotic, whereas only 34.6% of CFTR-defective cells had undergone apoptosis (Fig. 7A) . Western blot analysis confirmed an increased expression of caspase-3, that was inhibited in the presence of an anti-TNF-a antibody (Fig.7B) .
A very low cytochrome c release was observed in CFTR-defective cells treated either with acute (Fig.6 D-F) . Recent reports have shown that neutrophil elastase is able to induce detachment-induced apoptosis of human airway smooth muscle cells (23); furthermore , Preston et al. (24) reported that the release of neutrophilic proteases, such as PR3 and human neutrophil elastase, can result in their entry into endothelial cells coincident with the activation of proapoptotic-signaling events through ERK, JNK, and p38 MAPK. In this context, we wondered whether the high levels of neutrophil elastase in the SSP from CF patients could be, at least in part, responsible for SSP-induced epithelial cell apoptosis. To test this hypothesis, in some experiments we assessed apoptosis in both wild-type and CFTR-defective epithelial cells in the absence or presence of the neutrophil elastase inhibitor aI-AT. The addition of aI-AT to the cell cultures did not significantly affect SSP-induced apoptosis either in wild-type (cells treated with stable SSP: 38±4.5% of apotptotic cells, cells treated with stable SSP + aI-AT: 32±5.1%; cells treated with 
Effect ofsSP on NF-KB activation
Recent studies have reported higher constitutive expression and increased activation of NF-KB in unstimulated CF airway epithelial cells compared with non-CF cells (25) (26) (27) (28) . NF-KB has been shown to exert an anti-apoptotic effect in many cell lines including respiratory epithelial cells (29) (30) . Thus , to investigate whether NF-KB activation would explain the lower susceptibility to SSP-induced apoptosis ofCFTR-defective cells, we examined the expression of NF-KB p65, NF-KB p50, and of the cytosolic IKB-a inhibitor in unstimulated and SSPtreated wild-type and CFTR-defective cells.
Western blot analysis carried out on cell Iysates showed decreased levels of NF-KB p65 and NFInt. J . Immunopalhol. Pharmacol. 86]
DISCUSSION
This study shows that a) sputum sol phase obtained from CF patients, both at clinical stability and more markedly at the time of an acute exacerbation, induces an upregulation of endothelial adhesion molecules on human microvascular endothelial cells, associated with an increase of PMN adhesion to these cells; b) sputum sol phase from CF patients, particularly at the time of an acute exacerbation, is also capable of inducing both necrosis and apoptosis of airway epithelial cells, that is mainly mediated by TNF-a. and the associated activation of caspase-S and caspase-3; c) CFTR-defective cells result to be less susceptible to SSP-induced apoptosis, that was less marked and delayed as compared with wild-type cells.
Airway inflammation is now recognized as a major factor in the development of lung injury in cystic fibrosis, and it has been shown that it is present even in patients in stable clinical conditions (3:5, 12, 31) .
The recruitment and migration of inflammatory cells from vascular compartments into the lung involve both.the release of soluble mediators and the upregulation of adhesion molecules on the surface of leukocytes and activated endothelial cells. Whereas the role of chemotactic factors and proinflammatory cytokines in neutrophil recruitment in CF has been widely documented (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , in contrast, the role of adhesion molecules in maintaining airway inflammation in CF has been less investigated. Our observation that airway secretions obtained from CF patients, particularly at the time of acute exacerbations, increase the expression of ICAM-I, E-selectin, and VCAM-I on human microvascular endothelial cells is the first evidence confirming that the high levels of inflammatory mediators in CF airways are able to induce a persistent upregulation of adhesion molecules on vascular endothelial cells, which in tum contributes to the chronic neutrophil influx in the CF lung.
The remarkable upregulation of endothelial adhesion molecules induced by SSP obtained at the time of an acute exacerbation may be due to the further increase in concentrations of inflammatory cytokines and/or to the further increase of neutrophil proteases in the airways, which have been shown Cutture conditi ons KB p50 in the cytoplasm of SSP-treated epithelial cells (Fig. 8) , associated with a corresponding increase in the cell nuclei (data not shown), and a parallel decreased expression of the cytosolic hill-a. inhibitor in both wild type and CFTR-defective cells (Fig. 8) , suggesting NF-KB activation and nuclear traslocation. Consistent with previous results, increased baseline levels of p65 and p50 proteins were observed in the cytoplasm (Fig. 8) as well as in the nuclei ofCFTR-defective cells compared with wild-type cells, suggesting that a constitutive higher expression ofNF-KB could contribute to the delayed and less marked apoptosis observed in these cells. to upregulate adhesion molecule expression (20, (32) (33) (34) . Consistent with the first hypothesis, we have previously shown that the concentrations of inflammatory cytokines increase in CF airways at the time of acute exacerbations, and are reduced by antibiotic treatment (35) . Concerning the role of neutrophil proteases, our results differ from those of Champagne et al. In the present study, we found that, despite the high levels of elastase activity in CF sputum, the addition of aI-AT to the endothelial cell cultures does not affect either SSP-induced ICAM-I upregulation or s-ICAM release. These discrepancies may be related to the differences in cell types (Champagne et al. used U937 promonocytic and MT-2 and MT-4 T lymphocyte cell lines, whereas Ishihara et al. used rat endothelial cells, and we used human endothelial cell lines); furthermore, Champagne et al. showed that the extent of ICAM-I cleavage was variable with sputum from different patients, and followed closely the severity of the disease, being particularly marked with sputum obtained from patients with very severe clinical conditions. However, these discrepant results suggest that further in vivo studies are needed to define the effect ofneutrophil proteases on endothelial adhesion molecules in CF. Our finding that SSP obtained from CF patients at the time of an acute exacerbation significantly increases PMN adhesion to endothelial cells supports the concept that during recurrent exacerbations of the disease an increased recruitment of neutrophils occurs into the airways, which perpetuates lung damage .
SSP obtained from CF patients, particularly at the time of an acute exacerbation, was also capable of inducing necrosis and apoptosis of airway epithelial cells, both wild-type and CFTRdefective; CFTR-defective cells were, however, less susceptible to SSP-induced apoptosis; this could be the consequence of the higher constitutive NF-KB expression that we observed in these cells. NF-KB is an important transcriptional activator which has been shown to exert anti-apoptotic effects in many cell lines, including respiratory epithelial cells (29) (30) . Consistent with our results , previous studies showed a higher constitutive expression and increased activation of NF-KB in CF airway epithelial cells compared with non-CF cells (25) (26) (27) (28) . Our findings, however, differ from those of Becker et al. (36) , who, using primary cultures of differentiated CF and non-CF cells, did not find significant differences in NF-KB activation, at baseline or after stimulation with bacterial products. These discrepancies may be related to differences in cell types, culture conditions, and nature and timing of the stimulus; furthermore, IkB-a. Further in vivo studies, thus, are needed to define the state of activation ofNF-KB in CF airway epithelial cells. Very recent studies (12) show that abnormal ceramide accumulation occurs in the respiratory tract of uninfected CFTR-deficient mice, as well as in respiratory epithelial cells of subjects with cystic fibrosis, as a consequence of the CFTR defect, and that it leads to constitutive increased inflammatory response, respiratory epithelial cell death, and high susceptibility to severe P. aeruginosa infection. The accumulation of ceramide on the respiratory epithelium may still increase after the onset ofchronic P. aeruginosa infection, inducing a vicious cycle that augments tissue destruction and remodeling by increasing inflammation (12) . Ceramide has been shown to induce apoptosis, a property common with many agents that cause its cellular accumulation, including TNF a (12, 37-38); as we observed that the SSP-induced epithelial cell apoptosis was mainly mediated by TNF a, we cannot exclude that ceramide accumulation induced by this cytokine would playa role. Our observation of a preferential involvement of the extrinsic pathways of apoptosis in CFTR-defective cells seems to be consistent with this possibility. In this context, our observation that SSP from CF patients, and particularly from patients with an acute exacerbation, induces both necrosis and apoptosis of airway epithelial cells, further strengthens the concept that the inflammatory process occurring in the CF airways, as a consequence of the CFTR defect, and enhanced by recurrent infectious exacerbations, have the potential to amplify lung damage.
In conclusion, this study shows that inflammatory mediators in airway secretions from CF patients, both at clinical stability and even more at the time of an acute exacerbation, are able to upregulate in vitro endothelial adhesion molecules and increase neutrophil adhesion to endothelial cells, as well as to induce necrosis and apoptosis in both wild-type and CFTR-defective airway epithelial cells.
In this context, further identification of inflammatory mediators in CF airway secretions is of great importance in designing therapeutic intervention, aimed at modulating the inflammatory response and, thereby, the severity of airway wall damage.
